Sandbox Reserved 1645
From Proteopedia
(Difference between revisions)
Line 33: | Line 33: | ||
== Diseases caused by mutation == | == Diseases caused by mutation == | ||
- | + | Dominant mutations in the fibrillin-1 gene cause [https://www.omim.org/entry/154700?search=marfan%20syndrome&highlight=%28syndrome%7Csyndromic%29%20marfan Marfan syndrome (MFS)] and illustrate the physiological functions of elastic fibers. Most of the thousand known '''fibrillin-1''' mutations make the protein unstable and susceptible to proteolysis. Other point mutations interfere with folding. All patients are heterozygotes. | |
+ | Elastic fibers of patients with ''Marfan syndrome'' are poorly formed, accounting for most of the pathological changes. Most dangerously, weakness of elastic fibers in the aorta leads to an enlargement of the vessel, called an aneurysm, which is prone to rupture, with fatal consequences. Prophylactic replacement of the aorta with a synthetic graft and medical treatment with drugs that block adrenergic receptors allow patients a nearly normal life span. In some patients, a floppy mitral valve in the heart causes reflux of blood from the left ventricle back into the left atrium. Weak elastic fibers that suspend the lens of the eye result in dislocation of the lens and impaired vision. Weak elastic fibers result in lax joints and curvature of the spine. Most affected patients are tall, with long limbs and fingers, but the connection of these features to fibrillin is not known | ||
+ | |||
It exists nearly 1 000 different mutations possible in this gene (<scene name='86/868178/Mutations/1'>possible mutations of amino acid residues associated with the MFS in the 3D model</scene>), but the most common one is a substitution of guanine by thymine at the 1538 nucleotide of the transcript. This type of mutation leads to a non-synonymous amino acid substitution '''Cys (cysteine) to Phe (phenylalanine)''' at the 528 position on the Fibrillin-1 gene. Because this cysteine is present in the calcium-binding domain's polypeptide chain, the epidermal growth factor-like domain's structure of FBN1 is modified by affecting the <scene name='86/868178/Disulfide_bridges/1'> disulfide bridge</scene>. The calcium cation cannot bind properly to the <scene name='86/868178/Ca_binding_site/1'> cb-EGF unit </scene> and therefore there is no stabilization of cb-EGF interdomain which causes defects in connective tissue. We can thus detect the Marfan syndrome by an increase of TGF-bp in the blood because the factors cannot bind to the protein due to a change in the binding domain's structure. <ref>E. Martínez-Quintana, F. Rodríguez-González, P. Garay-Sánchez, and A. Tugoresb. (2014).A Novel Fibrillin 1 Gene Mutation Leading to Marfan Syndrome with Minimal Cardiac Features. ''Molecular Syndormology'', volume (5), 236-240.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188161/</ref> | It exists nearly 1 000 different mutations possible in this gene (<scene name='86/868178/Mutations/1'>possible mutations of amino acid residues associated with the MFS in the 3D model</scene>), but the most common one is a substitution of guanine by thymine at the 1538 nucleotide of the transcript. This type of mutation leads to a non-synonymous amino acid substitution '''Cys (cysteine) to Phe (phenylalanine)''' at the 528 position on the Fibrillin-1 gene. Because this cysteine is present in the calcium-binding domain's polypeptide chain, the epidermal growth factor-like domain's structure of FBN1 is modified by affecting the <scene name='86/868178/Disulfide_bridges/1'> disulfide bridge</scene>. The calcium cation cannot bind properly to the <scene name='86/868178/Ca_binding_site/1'> cb-EGF unit </scene> and therefore there is no stabilization of cb-EGF interdomain which causes defects in connective tissue. We can thus detect the Marfan syndrome by an increase of TGF-bp in the blood because the factors cannot bind to the protein due to a change in the binding domain's structure. <ref>E. Martínez-Quintana, F. Rodríguez-González, P. Garay-Sánchez, and A. Tugoresb. (2014).A Novel Fibrillin 1 Gene Mutation Leading to Marfan Syndrome with Minimal Cardiac Features. ''Molecular Syndormology'', volume (5), 236-240.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188161/</ref> |
Revision as of 15:04, 9 January 2022
This Sandbox is Reserved from 26/11/2020, through 26/11/2021 for use in the course "Structural Biology" taught by Bruno Kieffer at the University of Strasbourg, ESBS. This reservation includes Sandbox Reserved 1643 through Sandbox Reserved 1664. |
To get started:
More help: Help:Editing |
Fibrillin-1
|
References
- ↑ Handford, P. A. (2000). Fibrillin-1, a calcium binding protein of extracellular matrix. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1498(2), 84–90. https://doi.org/10.1016/S0167-4889(00)00085-9
- ↑ Zhang H, Apfelroth SD, Hu W, Davis EC, Sanguineti C, Bonadio J, Mecham RP, Ramirez F (March 1994). "Structure and expression of fibrillin-2, a novel microfibrillar component preferentially located in elastic matrices". The Journal of Cell Biology. 124 (5): 855–63. doi:10.1083/jcb.124.5.855. PMC 2119952. PMID 8120105.
- ↑ Corson GM, Charbonneau NL, Keene DR, Sakai LY (March 2004). "Differential expression of fibrillin-3 adds to microfibril variety in human and avian, but not rodent, connective tissues". Genomics. 83 (3): 461–72. doi:10.1016/j.ygeno.2003.08.023. PMID 14962672.
- ↑ Gansner JM, Madsen EC, Mecham RP, Gitlin JD (October 2008). "Essential role for fibrillin-2 in zebrafish notochord and vascular morphogenesis". Developmental Dynamics. 237 (10): 2844–61. doi:10.1002/dvdy.21705. PMC 3081706. PMID 18816837.
- ↑ Sandra Schrenk Carola Cenzi Thomas Bertalot Maria Teresa Conconi Rosa Di Liddo, (2017), pages: 1213-1223,https://doi.org/10.3892/ijmm.2017.3343
- ↑ https://www.genecards.org/cgi-bin/carddisp.pl?gene=FBN1
- ↑ Robert N. Ono, Gerhard Sengle, Noe L. Charbonneau, Valerie Carlberg, Hans Peter Bächinger, Takako Sasaki, Sui Lee-Arteaga, Lior Zilberberg, Daniel B. Rifkin, Francesco Ramirez, Mon-LiChu, Lynn Y.Sakai. (2009). Latent Transforming Growth Factor β-binding Proteins and Fibulins Compete for Fibrillin-1 and Exhibit Exquisite Specificities in Binding Sites. Journal of Biological Chemistry, volume (284). https://www.sciencedirect.com/science/article/pii/S0021925818665056
- ↑ Shazia S. Chaudhry, Stuart A. Cain, Amanda Morgan, Sarah L. Dallas, C. Adrian Shuttleworth, Cay M. Kielty; Fibrillin-1 regulates the bioavailability of TGFβ1. J Cell Biol 29 January 2007; 176 (3): 355–367. doi: https://doi.org/10.1083/jcb.200608167
- ↑ Quondamatteo F, Reinhardt DP, Charbonneau NL, Pophal G, Sakai LY, Herken R (December 2002). "Fibrillin-1 and fibrillin-2 in human embryonic and early fetal development". Matrix Biology. 21 (8): 637–46. doi:10.1016/s0945-053x(02)00100-2. PMID 12524050. / Ammash NM, Sundt TM, Connolly HM (January 2008). "Marfan syndrome-diagnosis and management". Current Problems in Cardiology. 33 (1): 7–39. doi:10.1016/j.cpcardiol.2007.10.001. PMID 18155514. / Votteler M, Berrio DA, Horke A, Sabatier L, Reinhardt DP, Nsair A, Aikawa E, Schenke-Layland K (June 2013). "Elastogenesis at the onset of human cardiac valve development". Development. 140 (11): 2345–53. doi:10.1242/dev.093500. PMC 3912871. PMID 23637335.
- ↑ E. Martínez-Quintana, F. Rodríguez-González, P. Garay-Sánchez, and A. Tugoresb. (2014).A Novel Fibrillin 1 Gene Mutation Leading to Marfan Syndrome with Minimal Cardiac Features. Molecular Syndormology, volume (5), 236-240.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188161/
- ↑ TGFBR2.https://www.omim.org/entry/190182?search=TGFBR2&highlight=tgfbr2
- ↑ Am J Hum Genet.(1999), Cysteine Substitutions in Epidermal Growth Factor–Like Domains of Fibrillin-1: Distinct Effects on Biochemical and Clinical Phenotypes, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1288233/